NCT05679921 is a Phase 2 clinical trial of pembrolizumab, pazopanib in Soft Tissue Sarcoma, sponsored by Yonsei University.

Who is sponsoring NCT05679921?

NCT05679921 is sponsored by Yonsei University.

What drugs are being tested in NCT05679921?

Interventions in NCT05679921: pembrolizumab, pazopanib.

What condition does NCT05679921 study?

NCT05679921 studies Soft Tissue Sarcoma.

Is NCT05679921 still recruiting?

NCT05679921 is currently recruiting now. Last updated 16 July 2025.

Last reviewed 2025-07-16 · How we verify

NCT05679921

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma

Recruiting now Phase 2 Last updated 16 July 2025

What this trial tests

Phase 2 trial testing pembrolizumab, pazopanib in Soft Tissue Sarcoma in 116 participants. Currently enrolling.

Timeline

1 March 2024

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	Yonsei University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	116
Start date	1 March 2024
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	1 location across South Korea

Drugs / interventions tested

pembrolizumab, pazopanib — full drug profile →

Conditions studied

Soft Tissue Sarcoma — all drugs for Soft Tissue Sarcoma →

Sponsor

Yonsei University

Who can join

Adults 20 to 80, any sex, with Soft Tissue Sarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, randomized, phase II study to evaluate the clinical activity of pembrolizumab in combination with pazopanib compared to pazopanib monotherapy.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial.
Cho HJ, Yun KH, Shin SJ, Lee YH, et al · · 2024 · cited 26× · PMID 38263321 · DOI 10.1038/s41467-024-44875-2
Biomarkers for immune checkpoint inhibition in sarcomas - are we close to clinical implementation?
Yiong CS, Lin TP, Lim VY, Toh TB, et al · · 2023 · cited 26× · PMID 37612756 · DOI 10.1186/s40364-023-00513-5
Efficacy of tyrosine kinase inhibitors in patients with advanced or metastatic sarcomas after prior chemotherapy: A meta-analysis.
Li W, Liu L, Liang Z, Lai H, et al · · 2024 · cited 2× · PMID 38489731 · DOI 10.1097/md.0000000000037423
Challenges and Progress for Treatment of Malignant Peripheral Nerve Sheath Tumors in the Context of Recent Successes for Sarcoma Therapy.
Callaghan JF, Mattingly RR. · · 2025 · PMID 41374983 · DOI 10.3390/cancers17233781
MAPK-targeted therapies in non-gastrointestinal stromal tumor soft tissue sarcomas: current landscape and future directions.
Al Jarroudi O, El Bairi K, Brahmi SA, Afqir S. · · 2025 · PMID 40909947 · DOI 10.3389/fonc.2025.1418537
Real-world data on immune checkpoint inhibitors in advanced sarcomas across multiple European institutions.
Kokkali S, Dolcan A, Boye K, Kyriazoglou A, et al · · 2025 · PMID 40495323 · DOI 10.2340/1651-226x.2025.43135

Verify or expand the search:

Other recruiting trials for Soft Tissue Sarcoma

Currently open trials in the same condition.

NCT07261631 — Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors · Phase 1 · recruiting
NCT07243626 — Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma · Phase 2 · recruiting
NCT07049848 — SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radi · Phase 2 · recruiting
NCT06962072 — Outcomes Following Limb Sparing Surgery for Soft Tissue Sarcoma · recruiting
NCT06905132 — Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma · Phase 2 · recruiting

Other Yonsei University trials

Trials by the same sponsor.

NCT07547592 — Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma · Phase 2 · not yet recruiting
NCT07524101 — Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD · NA · not yet recruiting
NCT07506629 — Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty · NA · not yet recruiting
NCT07515716 — Effects of High Flow Humidified Oxygen on Umbilical Artery Acid-base Balance in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
NCT07507188 — Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05679921 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yonsei University
Last refreshed: 16 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05679921.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing